UPDATE: Citi On Regeneron Continues 'to remain bullish on Dupixent and see $10B peak sales vs current run-rate of ~$2.5B within 3 years of launch. We are less concerned about the Dupi competition as we think the safety profile of Dupi sets it apart'

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com

Benzinga · 11/07/2019 18:46